TUCSON, Ariz., June 7, 2022 — Critical Path Institute (C-Path) and MitoAction today announced a joint collaboration to incorporate patient data for rare mitochondrial disorders into C-Path’s Rare Disease...
Sarah McGee fell backwards, collapsing into the red armchair as her mind suffocated under the pressure. Having just returned from yet another brutal doctor’s appointment, her husband, Kelly, was...
(WNDU) – The last day of February is Rare Disease Day, a day aimed to raise awareness about rare diseases. “There are many millions of Americans that are currently...
“’Give her time and she’ll surely catch up,’ they said. ‘She’ll be fine.’ … When Dalia was 9, she lost her ability to walk, talk, eat, and breathe without...
When little Noah Barlow came rushing into the world at 29 weeks and weighing just over one kilogram, his parents had no idea of the harrowing journey that lay...
FOR RELEASE FRIDAY, FEB. 4 AT 11:30AM TK2d Patient Voices Elevated at FDA United Mitochondrial Disease Foundation, MitoAction Champion First Ever Listening Session for this Rare Disease PITTSBURGH, Pa.,...
Published on Jan 25, 2022 in CHOP News Researchers from the Mitochondrial Medicine Frontier Program at Children’s Hospital of Philadelphia (CHOP) have developed a comprehensive sequencing test specifically for mitochondrial DNA (mtDNA). This new...
CHOP Researchers Develop New Clinical Diagnostic Test to Identify Genetic Sources of Mitochondrial Disease New test analyzes mitochondrial DNA to find and quantify certain variations and deletions, providing a...
The Metabolic Genetic Testing Market is likely to grow on a robust note in the next decade. The next decade would be seeing the integration of telehealth services with...
January 10, 2022 02:00 ET | Source: Khondrion Khondrion completes enrolment in KHENERGYZE Phase IIb trial evaluating sonlicromanol in adult patients with MELAS spectrum disorders NIJMEGEN, the Netherlands – 10 January 2022: Khondrion, a clinical stage biopharmaceutical company discovering and...